Fusion Antibodies Plc Statistics
Want to see GB:FAB full AI Analyst Report?
Fusion Antibodies Plc (FAB) Stock Statistics & Valuation Metrics
Total Valuation
Fusion Antibodies Plc has a market cap or net worth of GBX 5.32M. The enterprise value is GBX 13.92M.
- Market Cap
- GBX 5.32M
- Enterprise Value
- GBX 13.92M
Share Statistics
Fusion Antibodies Plc has 125,156,876 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 125,156,876
- Owned by Insiders
- 4.55%
- Owned by Institutions
- ―
Financial Efficiency
Fusion Antibodies Plc’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -99.85%.
- Return on Equity (ROE)
- -0.71
- Return on Assets (ROA)
- -0.42
- Return on Invested Capital (ROIC)
- -99.85%
- Return on Capital Employed (ROCE)
- -1.05
- Revenue Per Employee
- 78.15K
- Profits Per Employee
- -42.56K
- Employee Count
- 27
- Asset Turnover
- 0.77
- Inventory Turnover
- 2.78
Valuation Ratios
The current PE Ratio of Fusion Antibodies Plc is -4.29. Fusion Antibodies Plc’s PEG ratio is -0.05.
- PE Ratio
- -4.29
- PS Ratio
- 2.52
- PB Ratio
- 3.09
- Price to FCF
- -4.55
- Price to Operating Cash Flow
- -4.52
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Fusion Antibodies Plc had revenue of 2.11M and earned -1.15M in profits. Earnings per share was -0.01.
- Revenue
- 2.11M
- Gross Profit
- 1.10M
- Operating Income
- -1.98M
- Pretax Income
- -1.15M
- Net Income
- -1.15M
- EBITDA
- -1.85M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -1.11M and capital expenditures -60,000, giving a free cash flow of -1.17M billion.
- Operating Cash Flow
- -1.11M
- Free Cash Flow
- -1.17M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Fusion Antibodies Plc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -21.98%
- Earnings Yield
- -22.92%
Stock Price Statistics
- Beta
- -0.74
- 52-Week Price Change
- -66.00%
- 50-Day Moving Average
- 8.59
- 200-Day Moving Average
- 11.51
- Relative Strength Index (RSI)
- 19.91
- Average Volume (3m)
- 627.91K
Important Dates
Fusion Antibodies Plc upcoming earnings date is Dec 07, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 14, 2026
- Next Earnings Date
- Dec 07, 2026
- Ex-Dividend Date
- ―
Financial Position
Fusion Antibodies Plc as a current ratio of 2.82, with Debt / Equity ratio of 20.41%
- Current Ratio
- 2.82
- Quick Ratio
- 2.39
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.38
- Interest Coverage Ratio
- -99.05
Taxes
In the past 12 months, Fusion Antibodies Plc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Fusion Antibodies Plc EV to EBITDA ratio is -3.06, with an EV/FCF ratio of -3.94.
- EV to Sales
- 2.18
- EV to EBITDA
- -3.06
- EV to Free Cash Flow
- -3.94
- EV to Operating Cash Flow
- -4.15
Balance Sheet
Fusion Antibodies Plc has GBX 1.04M in cash and marketable securities with GBX 331.00K in debt, giving a net cash position of GBX 712.00K billion.
- Cash & Marketable Securities
- GBX 1.04M
- Total Debt
- GBX 331.00K
- Net Cash
- GBX 712.00K
- Net Cash Per Share
- GBX 0.01
- Tangible Book Value Per Share
- GBX 0.01
Margins
Gross margin is 52.32%, with operating margin of -95.02%, and net profit margin of -54.45%.
- Gross Margin
- 52.32%
- Operating Margin
- -95.02%
- Pretax Margin
- -54.45%
- Net Profit Margin
- -54.45%
- EBITDA Margin
- -71.37%
- EBIT Margin
- -77.39%
Analyst Forecast
The average price target for Fusion Antibodies Plc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 7.38%
- EPS Growth Forecast
- 44.13%
Scores
- Smart Score
- ―
- AI Score
- 43

